Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 19 Show results per page	View Search Criteria \| Help With Results

Last Modified: 12/1/1998


1.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469

Last Modified: 9/1/2001 First Published: 7/1/2000


2.		Phase III Randomized Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) With or Without Monoclonal Antibody HuG1-M195 In Patients With Refractory or Relapsed Acute Myelogenous Leukemia (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				PDL-195-301 MSKCC-00029, UCLA-9910050, NCI-G00-1819, NCT00006045

Last Modified: 6/1/1994


3.		Phase II Study of MOAB HuG1-M195 in Patients with Chronic Myelogenous Leukemia in Chronic or Accelerated Phase (Summary Last Modified 06/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				12 and over								MSKCC-93111 NCI-V94-0350

Last Modified: 7/1/1994


4.		Phase II Study of MOAB HuG1-M195 for Acute Promyelocytic Leukemia in TRA-Induced Remission (Summary Last Modified 07/94)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 12								MSKCC-93117 NCI-V94-0359

Last Modified: 6/1/2000


5.		Phase II Study of MOAB HuM195 as Early Post Remission Therapy Followed by Cytarabine and Idarubicin and Maintenance with HuM195 for Acute Promyelocytic Leukemia in Clinical Complete Remission (Summary Last Modified 06/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				12 and over				NCI				MSKCC-94088A3 NCI-H94-0571, NCT00002609

Last Modified: 7/12/2007


6.		Phase II Study of MOAB HuM195/IL-2 for Relapsed or Refractory Myeloid Leukemia (Summary Last Modified 05/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 16								MSKCC-95009 NCI-V95-0631

Last Modified: 7/1/2001


7.		Phase II Study of High-Dose Cytarabine with a Single High Dose of Idarubicin for Newly Diagnosed Acute Myelogenous Leukemia: the AML-3 Protocol (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-96044 NCI-V96-0941, NCT00002800

Last Modified: 12/1/1999 First Published: 2/1/1998


8.		Phase II Randomized Study of Recombinant Humanized Anti-CD33 Monoclonal Antibody (HuM195) in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				16 and over				Pharmaceutical / Industry				MSKCC-97103 PDL-3-201, NCI-G97-1367

Last Modified: 2/1/2001 First Published: 9/1/1999


9.		Phase II Study of Monoclonal Antibody HuG1-M195 in Patients With High Risk Primary Myelodysplastic Syndromes (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								EORTC-13981 NCT00003984

Last Modified: 11/1/2001 First Published: 8/1/2000


10.		Phase II Study of Monoclonal Antibody HuG1-M195 in Patients With Acute Myelogenous Leukemia With Regimen Failure On the Control Arm of PDL Study 195-301 (Summary Last Modified 11/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-9910096 PDL-195-302, NCI-G00-1823, NCT00006084

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute